HLA-A2 § melanomas express common melanoma-associated antigens (Ags) recognized in vitro by autologous cytotoxic T lymphocytes (CTL). However, it is not known whether tumor Ags can drive in vivo a selective accumulation/expansion of Ag-specific, tumor-infiltrating T lymphocytes (TIL). Therefore, to evaluate this possibility, 39 CTL clones isolated from several independent mixed lymphocyte tumor cultures (MLTC) of TIL and peripheral blood lymphocytes (PBL) of an HLA-A2 + melanoma patient and selected for T cell receptor (TCR)-dependent, HLArestricted tumor lysis, were used for analysis of TCR c~ and ~ chain structure by the cDNA polymerase chain reaction (PCR) technique with variable gene-specific primers followed by sequencing. Despite absence of oligoclonality in fresh TIL and PBL, as well as in T ceils of day 28 MLTC (day of cloning), sequence analysis of TCR c~ and ~ chains of TIL clones revealed a dominance of a major category of melanoma-specific, HLA-A2-restricted T cells expressing a Vc~8.2/JotAP511/Cot and Vf12.1/DB1/J31.1/C/31 TCR. The same TCR was also found in 2 out of 14 PBL clones. The other PBL clones employed a Vow2.1 gene segment associated with either Vfl13.2, 14, or w22. Clones A81 (Vce2.1/JotIGRJoL04/Ccr and V314/D31/Jfll.2/Cj31) and A21 (Vce8.2/JoeAP511/Col and V/32.1/D/31/J31.1/C31), representative of the two most frequent TCR of PBL and TIL, respectively, expressed different lyric patterns, but both were HLA-A2 restricted and lysed only HLA-A2 + melanomas and normal melanocytes, thus indicating recognition of two distinct HLA-A2-associated and tissue-related Ags. Finally, by the inverse PCR technique, the specific TCR 3 chain (V32.1/Dfll/J31.1/C3I) expressed by the dominant TIL clone was found to represent 19 and 18.4% of all V/32 sequences expressed in the fresh tumor sample and in the purified TIL, respectively, but <0.19% of Vfl2 + sequences expressed in PBL. These results are consistent with the hypothesis that a clonal expansion/accumulation of a melanocyte-lineage-specific and HLA-A2-restricted T cell clone occurred in vivo at the site of tumor growth.
S
tudies on the T cell immune response to human melanoma have provided evidence that the mechanism of recognition of melanoma Ags by CTL is similar to that of more conventional types of Ags, namely recognition of complexes between tumor-associated peptides and MHC class I molecules by a cell surface heterodimer receptor (TCR) composed of an oe and ~ chain (1-4). The first peptide-HLA complex recognized as a melanoma Ag has been recently identified (5) , but it is likely that melanomas from different patients or even from the same patient will express multiple Ags. In fact, distinct antigenic determinants, as well as different HLA class I alleles acting as restricting elements, have been defined on melanoma ceils by autologous T cell clones (1-4, 6, 7). Whether or not the degree of complexity of the melanoma Ag repertoire will be reflected in a corresponding repertoire of distinct TCR recognizing those Ags is unknown, but re-cent evidence from this laboratory is in agreement with the hypothesis that the CTL-mediated response to melanoma is polyclonal at the single patient level. This evidence comes from the observation that different CTL clones from the same patient may have similar antitumor reactivity but different TCR structure (8) .
Most of the studies that have addressed the question of TCR diversity in melanoma, or in other neoplastic diseases, have analyzed fresh or IL-2-cultured tumor-infiltrating T lymphocytes (TIL) 1 in the attempt to identify oligoclonal T cell populations characterized by a restricted set of different TCR gene segments. The identification of such a population of T cells, if present, could facilitate the study of the molecular mechanisms of the immune response and could provide a specific target for new immunotherapeutic strategies. Indeed, in agreement with the possibility of identifying oligoclonal T cell populations in the lymphoid infiltrate, a preferential expression of Vot7 TCR gene segment has been found in primary human uveal melanoma by PCR using V gene family specific primers in seven out of eight patients studied (9) . On the other hand, the TCR Vow/V/3 repertoire of fresh TIL from metastatic lesions of cutaneous melanoma has been found to vary widely even in the same patient (10, 11) . Furthermore, after long-term culture in IL-2, TIL from metastatic melanoma may become oligoclonal in their TCR f3 chain rearrangements (12) (13) (14) , although it is difficult to assess the mechanism of this process.
The analysis of TCR structure of whole TIL populations, however, will hardly allow one to link the information on TCR structure and repertoire with the functional involvement of those TCR in the antitumor response, since one cannot distinguish between tumor-specific and bystander lymphocytes with no antitumor reactivity. Moreover, this approach does not allow the association of any defined combination of TCR ol and/3 chains with a precise antigenic specificity, and thus fails to provide a clear answer to the question of whether melanoma can drive, at the site of tumor growth, a preferential expansion/accumulation of tumorspecific T cells recognizing melanoma Ags.
To address these issues, we initially determined the Vo~/Jol and VjffD/3/Jf3 TCR gene segments employed by a large set of TIL or PBL CTL clones from a HLA-A2 + melanoma patient. The results indicated that different TCR combinations can confer different antitumor specificity. Moreover, a dominant HLA-A2-restricted T cell clone expressing a Vc~8.2/ Jc~AP511/Col, VB2.1/DB1/J~l.1/CB1 TCR and directed to a melanocyte-lineage-associated Ag could be found in a majority of TIL clones independently isolated from different mixed lymphocyte tumor cultures (MLTC). By inverse PCR (IPCR), the nudeotide sequence corresponding to the specific TCR/3 chain of this dominant TIL clone was found to represent 18.4 and 19% of all V/32 + sequences in the fresh tumor sample and fresh, purified TIL, respectively, compared 1 Abbreviations used in this paper: IPCR, inverse PCR.; MLTC, mixed lymphocyte tumor culture; TIL, tumor-infiltrating lymphocyte.
with <0.19% of V/32 + sequences expressed in PBL. These results suggest that the expression on the tumor of a melanocyte-lineage-associated Ag can influence the tissue distribution of a T cell clone recognizing that Ag.
Materials and Methods
Neoplastic Cells. All mdanoma ceils used in this study were isolated from primary or metastatic lesions obtained from patients admitted for surgery to the Istituto Nazionah Tumori and were established in vitro as previously described (7) . In particular, Me9742/1 and Me9742/2 are a LN and a subcutaneous metastatic lesion, respectively, from melanoma patient 9742 (HLA-A2, -A24; -B13, -B18; -Cw6, -Cw7; -DR7, -DR11; and -DQ4). All tumors were kept in culture with RPM11640 (MA Bioproducts, Walkersville, MD) supplemented with 10% FCS. Normal human mdanocytes isolated from neonatal foreskin were cultured as described (15) . The biological and phenotypical characterization of the melanocytes has been reported recently (15) .
Lymphocyte Cultures. PBL and TIL were isolated as described (15) from peripheral blood and from one of the metastatic lesion (Me9742/2) of patient 9742. Immediately after isolation, PBL and TIL were divided into five separated aliquots, each initially cultured in 24-well plates (model 3424; Costar Corp., Cambridge, MA) at 2.5 x 10s-106 ceUs/ml in 2 ml of RPMI 1640 supplemented with 20% pooled human serum, antibiotics, and 50 IU/ml of rib2 (kindly provided by EuroCetus, Amsterdam, The Netherlands). PHA (Wellcome Diagnostics, Research Triangle Park, NC) at 1/zg/ml was added to one aliquot of TIL and PBL for mitogenic stimulation (TIL-PHA, PBL-PHA). MLTC were started by adding viable tumor cells at a lymphocyte/tumor ratio of 5:1 to each of the remaining cultures (named TIbl, -2, -3, -4 and PBL-1, -2, -3, -4). All independent MLTC, as well as mitogenic stimulations, were later transferred into 25 cm 2 flasks (model 25100B; Bibby Scientific Products Ltd., Stone, UK) and were restimulated every 7 d for 3 wk before cloning at the same conditions as above. Cloning was carried out from the four independent MLTC/TIL and the four independent MLTC/PBL cultures by limiting dilutions at 5, 1, 0.5, 0.25 cells/well in round-bottomed 96-well plates (model 3596; Costar Corp.) in the presence of 50 IU/ml rIL-2, irradiated (3,000 tad) aUogeneic PBL as feeders (5 x 104/well), and irradiated (10,000 rad) autologous tumor cells (5 x 10~/well). The plates were restimulated with autologous tumor and feeder cells after 1 wk of culture and screened at day 14 for the presence of growing clones. Clones were also derived by plating fresh PBL at 0.5 and 0.25 cells/well in the presence of aUogeneic irradiated PBL, 50 IU/ml rIL-2, and 1/zg/ml PHA. The probability of clonality for each done was calculated by Poisson statistics as described by Taswell et al. (16) , and only clones with a p value for clonality >0.95 were further analyzed. LAK cells were obtained by culturing PBL from normal donors in 500 IU/ml rlL-2. Samples from the surgical tumor specimen, freshly isolated TIL and PBL, MLTC and PHA cultures, and T cell clones, maintained for 2 wk after the initial screening in the absence of feeder cells, were stored at -70~ and used to extract total I~NA. TIL and PBL clones were also cryopreserved for future use.
Immunofluorescence Analysis. Indirect immunofluorescence was performed on autologous MLTC, PHA cultures, or T cell clones and analyzed on a FACS | (Becton Dickinson & Co., Mountain View, CA) as previously described (17) . mAbs used were OKT3 (anti-CD3, CRL8001; American Type Culture Collection (ATCC), RockviUe, MD), OKT4 (anti-CD4, CRLS002; ATCC), OKT8
(anti-CD8, CRL8014; ATCC), and WT31 (anti-TCIL-ot/fl, Becton Dickinson & Co.).
Cytotoxicity Assay. Cytotoxic activity ofMLTC, T cell clones, and LAK cells was measured in a standard 4-h slCr-release assay on panels of target tumors as previously described (7) . Inhibition of lysis by mAb to CD3 (OKT3), HLA class I (W6/32; SeraLab, Sussex, UK), HLA-A2, (CR.11.351; kindly provided by Dr. C. Rnsso, Cornell University, New York) (18) , and HI, A-DR (D1.12; kindly provided by Dr. K. Accolla, University of Verona, Italy) (19) was performed as described (7) with mAbs used at the final concentration of I/~g/ml. The percent specific lysis was calculated using the following formula: 100 Results were also expressed in lytic units (LU), where one LU is defined as the number of effectors required for 30% lysis and the number of LU present in 107 effector cells was calculated.
RNA Extraction and eDNA Synthesis. Total RNA from the different samples was prepared by the method of Chomczynski and Sacchi (20) using R.NAzoFMB (Cinna/Biotecx, Friendswood, TX). Single-stranded cDNA synthesis was carried out on 2 #g of total RNA with oligo-dT and Moloney murine leukemia virus-derived reverse transcriptase without RNase H activity (MMLV RT RNase H-, Superscript; Gibco BRL, Gaithersburg, MD) according to the manufacturer's instructions. After an ethanol precipitation, the cDNA was suspended in 40/~1 water.
PCR and IPCR. PCK was carried out by amplification of
TCg-ot and -/3 cDNA with oligonudeotide primers complementary to TCR V and C region sequences (9, 21) in 25/~1 of a reaction mixture containing 0.5/~1 of cDNA, 200/~M of each dNTP, 1/~M of each primer, and 0.625 U of Taq polymerase (Ampli Taq) on a DNA thermal cycler (all from Perkin Elmer Cetus Corp., Emeryville, CA). Reaction mixtures were subjected to 30 amplification cycles, each consisting of a 1-min denaturation step at 95~ a 1-min annealing step at 55~ and a 1-min extension step at 72~ Expression of Vo~ or V/~ genes was considered positive when a rearranged band (200-500 bp) was visualized on 2% agarose gels with ethidium bromide staining. For some experiments, Southern blot analyses were performed by transferring to nylon membranes (Hybond N +; Amersham International, Buckinghamshire, UK), 2% agarose gels containing a Vo~-Cc~ or V/gCB rearranged band, and hybridizing the blots with internal C region oligonucleotides (probes A and 13, respectively, see IPCR was performed according to the method described by Uematsu (22) . Briefly, double-stranded cDNA was synthesized by standard methods (23) from 1/~g of total RNA, blunt-ended with T4 DNA polymerase (New England Biolabs Inc., Beverly, MA), and circularized with T4 DNA ligase (Gibco BRL) in a volume of 10/~1. The ligated material (1 #1) was used as PCR template in a 50-/~1 reaction mixture. The couple of C region/3 chain primers used are identical to the ones described by Uematsu et al. (24) and are listed in Table 1 as oligonudeotides E (forward primer) and F (inverse primer), Oligonudeotides E and F contain artificial SalI and Nod sites, respectively, for subsequent directional cloning. At the end of the 30 amplification cycles (denaturation at 95~ for 40 s, annealing at 62~ for 40 s, and extension at 72~ for I min), the Klenow fragment of Escherichia coli DNA polymerase I (New England Biolabs Inc.) was added to ensure full-length DNA synthesis.
Cloning of PCR and IPCR Amplified Products. The amplified products of PCR obtained with V and C gene specific primers (9, 1233 Senti et al. Oligonudeotides. All oligonudeotides used were prepared on an automated DNA synthesizer (model 380A; Applied Biosystems, Foster City, CA). Sequences of oligonucleotides used as hybridization probes, IPCR, and sequencing primers are shown in Table  1 , whereas sequences of specific Vcd -~ Vot22, Ca, V/31 ~ V/320, C/8 PCK primers are listed elsewhere (9, 21) . For hybridization, oligonucleotides were endlabeled with [32p]ATP (Amersham International) and T4-polynucleotide kinase (New England Biolabs Inc.). Hybridization and washing conditions in order to match their target sequence perfectly were chosen according to the length and GC content, as described by Sambrook et al. (23) .
In particular, filters containing IPCR cDNA libraries were prehybridized for 5 h and then hybridized overnight at 42~ in a solution containing 3.2x SSC for probe D, 0.63x SSC for probe G, and 2.5x SSC for probe I3. In addition, prehybridization and hybridization buffer contained 5 x Denhardt's solution, 1% SDS, 50 mM Tris-HC1, pH 7.5, and 100/~g/ml salmon sperm DNA. 32p-labeled oligonudeotide probes were added to the hybridization buffer. Filters were then washed twice at room temperature and twice at 42~ in a washing solution containing 0.1% SDS and the SSC concentration used for hybridization.
Results

TCR Vot and V~ Usage by Fresh and Long-Term Cultured TIL and PBL from Patient 9742. MLTC lines TIL-1, -2, -3,
-4 and PBL-1, -2, -3, -4 were generated by culturing four independent aliquots of fresh TIL and PBL of patient 9742 with autologous melanoma cells (Me9742/2) and rlL-2. Each MLTC line was examined for TCR repertoire expression at day 28, day of cloning, and compared with uncultured TIL and PBL. This analysis was performed to see whether or not in vitro restimulation with autologous tumor is accompanied by oligoclonal expansion of T cells and to control for variability among multiple long-term cultures derived from the same pool of lymphocytes. An aliquot of either TIL or PBL, cultured for the same period of time in the presence of PHA, was included as control for polyclonal, Ag-independent stimulation, cDNAs were thus obtained from fresh TIL and PBL, from all MLTC and PHA lines, and were amplified by PCR for 30 cycles using Vow1 to Vo~22 and Vfll to Vfl20 specific primers in combination with a Col or a Cfl primer, respectively. Southern blots were hybridized with internal oligonucleotide probes for Cc~ (probe A, Table 1 ), Cfl (probe B, Table 1 ) in order to ascertain the specificity of amplification. The results obtained with fresh TIL (Fig. 1 ) indicated that their TCR Vo~ and Vfl repertoire was similar to that seen on fresh PBL ( Fig. 2 ) and, as described in a preliminary report (35), not oligoclonal. Furthermore, no oligoclonality was found in either population after in vitro restimulation with autologous melanoma (Figs. 1 and 2) since most of V~t and Vfl families present in fresh lymphocytes were still expressed after 28 d of MLTC. However, differences in the intensity of the hybridization signals were consistently observed. Increase of the hybridization signal of Vo~ 5, 11, and 14, either absence or decrease in Vo~ 6, 9, 12, and 15 and Vfl4, 10, 11, 17, 18, and 19 could be detected in at least three out of four MLTC-TIL cultures (Fig. 1) . Variations in MLTC-PBL cultures involved the increase of Vo~14 and the decrease or absence of V~x15 and V/34, 10, and 17. A consistent increase of Vc~2 was also observed in PBL-1, -3, and -4 ( Fig.  2) . The increase or decrease of the hybridization signals appeared to be associated with culture in the presence of autologous tumor since stimulation of TIL with PHA for the same period of time (28 d) failed to modify any of the above mentioned families and reflected the TCR Vc~ and V~3 usage of fresh TIL (Fig. 1) . The MLTC lines from TIL and PBL, all expressing a predominant CD3 +, CD8 +, TCR-cff~3 + phenotype (data not shown), were also tested for cytotoxicity against two different autologous lesions (Me9742/2 and Me9742/1) and six allogeneic melanomas. All MLTC lines from TIL and at least two of the MLTC lines from PBL (PBL-1 and -2) displayed a preferential lysis of the two autologous metastatic cell lines and of the only HLA-A2-matched allogeneic melanoma (Me10538) ( Table 2 ). TIL and PBL cultured with PHA and IL-2, but without autologous tumor cells, displayed a borderline cytotoxic activity on all targets.
Taken together, these data indicate that a preferential lysis of HLA-A2 + melanomas can be the result of all MLTC from TIL and of at least two MLTC from PBL. This cytolytic specificity, however, was not associated with oligoclonality at the level of TCIL. Therefore, we argued that only the analysis of CTL clones from the different MLTC could establish the correlation between functional specificity of the effectors and the structure of the corresponding TCR.
TCR Vot and V~ Usage by Antimelanoma T Cell Clones.
From all TIL and PBL lines previously analyzed, a total of 112 dones with a p value for clonality >0.95 were derived. Of these clones, 38 were selected for TCR Vot/VB analysis (24 clones from TIL and 14 from PBL) on the basis of (a) cytotoxic activity on the autologous tumor, and (b) inhibition of lysis by anti-CD3 and anti-HLA class I mAb. A T cell done (clone 119), obtained by direct cloning of fresh PBL with PHA, was also included in the analysis. All 39 CTL dones expressed a CD3 +, CD4-, CD8 +, TCR-ot//~ + phenotype (data not shown) and, as shown in Table 3 , displayed cytotoxic activity on the autologous melanoma with no or borderline activity on K562. Lysis of autologous melanoma by all these clones was specifically blocked by anti-CD3 (OKT3) and by anti-MHC class I (W6/32) mAbs (Table 3) . The Va and V~ gene segments utilized in TIL and PBL clones were examined by PCK, and the results are also shown in Table 3 . In agreement with the statistical prediction of donality, only one a and ~ rearranged transcript could be detected in all but one (PBL-1 done A78) of the clones studied.
The presence of two a and ~ chain transcripts in clone A78 is consistent with the hypothesis that it may not represent a true clone and, for this reason, it has not been further investigated. The variable fl chain expressed by PBL-1 clones A96, A100, and A89 and by the PBL-PHA clone 119 was 1237 semi et al.
identified by IPCR since no amplification could be detected with the VB primers used. All T cell clones derived from TIL-1, -2, -3, and -4 expressed a TCR composed by Va8 and VB2 V region genes (Table 3) , despite the fact that TIL clones were selected from four independent MLTC cultures, except for TIL-1 clones A25 (Va14/V/~2) and A36, for which only the a chain (VolS/non VB2) could be fully investigated because of the low amount of starting material. Moreover, PBL clones A93 and A147 derived from two independent MLTC cultures (PBL-1 and -4) expressed the same Va8 and VB2 transcripts 
.~.,GACACC, GCTCACOGTC, CT~. (Table 3 ). All other T cell clones, derived from PBL, preferentially used Vot2joined to either V313.2, V314, or VBw22 (Table 3) . No clones expressing Vcr and only two clones expressing V32 were found in 15 TIL clones derived from the same patient and lacking specificity for the autologous melanoma (data not shown).
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Sequencing of TCR cr and ~ cDNAs of TIL and PBL Clones.
Nucleotide sequence of TCR ot and ~ cDNAs indicated that V~8/V~2 clones A21, A50, A62, A70, A93, and A147 derived from the four independent in vitro MLTC cultures of TILs and from two independent cultures of PBLs, share exactly the same TCR. In fact, as shown in Fig. 3 , not only did they use the same Vot and VB family members, namely Vot8.2 (27) and a V~2.1 (30) recently designed as VB2.1a by Plaza et al. (32) , but they had identical oe and W(D)/Jjunctional sequences. VotS.2 was rearranged to a Jot segment identical to the published JotAP511 segment (26) except for a single base substitution, whereas VB2.1 was rearranged to DB1, J~1.1, and CB1 (34). DB1 segment was assigned on the basis of requirements for gene rearrangement since the exact identification of this region was impossible, due both to junctional and N region diversification and to the short length of the germline segment (25) . All remaining Vot8/V32 TIL clones did share the same junctional region as assessed by hybridization of Southern blots containing Vot8-Cot or V32-C3 rearranged bands with oligonudeotides C and D (Table 1) , specific for the junctional region of Vot8.2/Jc~AP511/Ca or VB2/D31/JBl.1/C31 chains, respectively (data not shown). Two other TCR configurations were identified by sequence analysis of PBL-1 clones, in addition to that composed by Vol8/V~2. In their ot chain, usage of the same V family member, Vc~2.1 (27) and presence of N region nucleotides at the V/J junction that create codons for a shared amino acid could be observed, whereas the/3 chain included V~13.2 (31) and V~14 (30) that belong to a subgroup of structurally related VB families (36) and the same JB1.2 gene segments. Apart from these similarities, both a and/J chain junctional regions are different in sequence and length. PBL-PHA clone 119 shared with PBL-1 clones the usage of Vot2.1 but employed the recently described VB w22 region (33) and was highly diverse in junctional sequences.
No predominant structural features were present when sequence of dominant TIL clones was compared with that of other TIL or PBL clones. As summarized in Table 4 Fig. 3 ) and TIL clones A37 and A54 (sharing a Vc~8.2/JotAP511/Cce -V~2.1/D~I/J~I.1/CB1 TCR (Fig. 3) have been recently shown to be HLA-A2 restricted and to recognize Ags expressed on autologous melanoma cells and on HLA-A2-matched normal melanocytes (15) . Moreover, specificity analysis of PBL clone A81 revealed that the antigen recognized was present on the majority of HLA-A2 aUogeneic melanomas (15) . We thus investigated whether TIL clone A21, representative of the dominant TCR found in TIL (i.e., Vc~8.2/JolAP511/Ccr -VB2.1/D~I/ JBI.1/C~I), expressed a similar or different pattern of lytic (Table 5 ). Only a borderline reactivity was seen by clone A21 on one HLA-A2 + fibroblast line (F1338/1). Taken together, these data suggest that TIL and PBL clones, expressing two different TCR, define distinct antigenic determinants preferentially expressed in cells of the melanocyte lineage. Both Ags are recognized in association with the HLA-A2 restriction element but are distinguishable on the basis of their broad or more restricted distribution on allogeneic HLA-A2 + melanomas. Concerning the other clones bearing different TCR, PBL clone 119 was not HLA-A2 restricted and was shown to recognize an antigenic determinant in association with a different, yet unidentified HLA class I allele (15) . TIL clones A36 and A25 and PBL clones A96, A100, and A89 could not be tested because of the insufficient amount of cells obtained to perform the specificity assay.
The V/D/J Sequence Associated with the Dominant HLA-A2-restricted TIL Clone Is Expressed More in the Tumor Sample and Fresh TIL than in PBL.
The identification from distinct TIL cultures of the same dominant done characterized by a Vc~8.2/Jc~AP511/C~-VB2.1/DB1/J~1.1/CBl TCR suggests, but does not prove, that a selective in vivo expansion/accumulation of this T cell occurred before the in vitro activation of the lymphocytes. To address this point, we screened cDNA libraries, constructed by IPCR using RNA extracted directly from the Me9742/2 surgical specimen, from freshly isolated TIL and from PBL, for B chain expression with specific oligonudeotide probes. Positive plaques for each oligonudeotide were then counted. Hybridization with an upstream CB probe (probe B, Table 1) showed that >80% of the clones contained TCR-~ sequences. As shown in Table  6 , the V~2 family sequences, as detected by hybridization with a V~2-specific oligunudeotide (probe G, Table 1 ), represented 10.2 and 11.7% of the total/3 chains in tumor samples and in TIL, respectively, vs. 6.5% in PBL. These results are in a similar range of frequency detected by two-color immunofluorescence followed by FACS | analysis using a cornmerciaUy available anti-VB2 mAb (mAb TCR V/32 No. 1149; Immunotech, Luminy, France) in association with a PEconjugated anti-CD3 mAb (LEU-4PE No. 7347; Becton Dickinson & Co.). This analysis indicated that 9% of CD3 + cells in PBL and 9.5% of CD3 + cells in TIL were positive for VB2 expression (data not shown). However, the B chain sequence corresponding to the junctional region of the dominant T cell clone was strikingly overrepresented in the tumor infiltrate. In fact, 19 and 18.4% of all V/32 + sequences in the surgical specimen and in the uncultured purified TIL extracted from the same sample were positive with oligonudeotide D. By contrast, no hybridizing clones were detected among 520 V/~2 +cDNA clones screened from the PBL sample. This indicates that the frequency of this specific sequence in the PBL had to be much lower than in the tumor sample and at least lower than 0.19% (1/520 = 0.00192) of all VB2 + sequences expressed in the PBL. In addition, all cDNA clones positive for oligonudeotide D were comprised in the V/32 + B chains and sequence analysis of five random oligonudeotide D + cDNA clones confirmed presence of the expected sequence (data not shown). To find out whether or not the V/32 + sequences that did not hybridize with oligonucleotide D were oligodonal, the primary structure of 10 randomly selected V~2 + cDNA clones derived from TIL was determined. All TCR V/32 chains sequenced were in frame and showed no evidence of clonality since none of the 10 sequences examined was repeated (data not shown).
These results indicate that the sequence corresponding to the specific TCR/3 chain expressed by an in vitro dominant TIL clone is preferentially expressed at the site of tumor growth in comparison to peripheral blood. This finding is consistent with the hypothesis that this T cell clone may have been subjected, in vivo, to a selective expansion/accumulation driven by an HLA-A2-associated melanocyte-lineage-specific Ag.
Discussion
The present study was aimed at the molecular characterization of TCR expressed by fresh and cultured TIL and PBL as well as by CTL clones isolated from MLTC of TIL and PBL of an HLA-A2 + melanoma patient in relation to their fine specificity and in vivo relevance. The analysis of TCR repertoire performed on fresh TIL indicated that the degree of diversity of this population of lymphocytes was similar to that found in circulating PBL. Furthermore, the same analysis performed on independent MLTC revealed that after 28 d of culture, both TIL and PBL were still as heterogeneous as uncultured cells in their TCR repertoire. This was in contrast with the emergence of a preferential lytic activity against autologous or allogeneic HLA-A2 + melanomas observed not only in all the TIL cultures, but also in at least two MLTC from PBL. These findings suggested that it was not possible to link any of the different TCR expressed in these cultures with the preferential lytic activity. The panel of clones derived from MLTC of TIL and PBL provided the opportunity to correlate TCR structure with antigenic specificity. Despite the large number of TCR Vo~ and V/~ families expressed (38) have demonstrated that specific antitumor CTL precursors are present in PBL and in TIL of cancer patients. However, when the antigenic specificity is similar, the knowledge of the molecular composition of the TCR is mandatory to assess whether or not specific CTL clones found in PBL or in TIL represent copies of the same T cell. The evidence described in this study, namely that the same T cell clone may be found in the periphery and at the tumor site but with different frequency, is consistent with the possibility that tumor-associated Ags can induce a bias in the tissue distribution of T cells recognizing them. The analysis of the TCR structure of different T cell clones isolated from the TIL or PBL of patient 9742 indicated that the HLA-A2-restricted cytolytic response to the tumor is mediated by at least two different TCR. The comparison of antigenic specificity of HLA-A2-restricted clones expressing these different TCR (PBL clone A81, bearing a Vcx2.1/V~14 TCR and TIL clone A21, bearing a Vo~8.2/V~2.1 TCR) confirms the results recently obtained with other clones from the same patient (15) and indicates that these effectors can recognize Ags expressed not only on autologous or allogeneic HLA-A2 + melanomas, but also on normal HLA-A2 + melanocytes. Furthermore, the antigenic determinants recognized by the two different CTL clones were expressed with different frequency among HLA-A2 + melanomas. These findings, therefore, are consistent with the hypothesis that the HLA-A2 molecule may act as a restricting element for more than one melanocyte-lineage-associated Ag and that distinct HLA-A2-peptide complexes are recognized by different TCtL. Further evidence supporting the hypothesis that the antigenicity of a human melanoma is based on a number of antigenic determinants recognized by distinct TCR, was provided by the analysis of the TCR. expressed by the non-HLA-A2-restricted CTL clone 119 (TCR Vc~2.1/VBw22), whose specificity has been recently described (15) . This result rules out any correlation between TCR Vo~2.1 usage and the restricting HLA-A2 molecule. Although six different TCR are expressed by the specific CTL clones characterized in this study, because of an insuf~cient number of cells, no information is available on the specificity of TIL clones A25 and A36 and of PBL-1 clones characterized by Vo12.1/Vf113.2 TCR that share some structural features with Vo~2.1/Vf114 TCR.
The information on the TCR structure of the CTL clones allowed us to correlate the antigenic specificity (namely HLA-A2-restricted recognition of a melanocyte-lineage-associated Ag) of the dominant category of TIL effectors with the relative frequency, in vivo, of the specific TCR fl chain sequence expressed by the same CTL clones. To analyze whether antitumor T cells expressing TCR gene segments that characterize dominant TIL clones were enriched in lymphocytes obtained directly from the tumor infiltrate, as compared with PBL, we hybridized cDNA libraries generated by IPCR with specific oligonucleotides for either TCR Vfl2 or the junctional fl region of the dominant TIL done. By this technique we could show that the specific junctional Vfl2.1/ Dill~Jr1.1 sequence represented 19 and 18.4% of all Vfl2 + cDNA clones in fresh TIL or in the surgical tumor specimen, respectively. By screening 520 Vfl2 +cDNA plaques derived from PBL libraries similarly constructed, no positive plaques could be detected, indicating that the frequency of this sequence had to be much lower in PBL than in TIL and at least lower than 0.19% (1/520) of the Vfl2 + sequences found in PBL. Interestingly, we found evidence that clones expressing this specific Vfl sequence were not absent from the peripheral circulation, as shown by the observation that two replicates of an effector bearing the specific Vfl2.1/Dfll/ Jfll.1/Cfl TCR fl chain were present among PBL clones isolated from the MLTC PBL-1 and PBL-4.
Taken together, the results obtained by the IPCR technique are consistent with the hypothesis that the expression on melanoma of a melanocyte-related antigen can alter the tissue distribution of a T cell clone recognizing that Ag. This process may be due to a phenomenon of progressive and selective accumulation of cells from the same circulating T cell clone at the site of tumor growth. This may have led to a progressive reduction in the relative abundance of the specific V/52.1/D/51/J/51.1 + TCR/5 sequences in the population of mRNA extracted from the PBL or, in other words, to a reduction in the frequency of the corresponding clone in the circulating pool. Alternatively, our results may also be explained assuming that one or more replicates of the TCR V/52.1/ D/51/J/51.1 + CTL clone underwent a phase of clonal expansion at the site of tumor growth, possibly as the result of Ag recognition. Both these processes can also explain the observation that the same CTL clone was found as independent replicates in distinct MLTC of TIL, a finding suggesting that the same T lymphocyte was present in multiple copies in the freshly purified TIL before this population was divided into four different MLTC.
Similar findings, pointing toward a different expression of TCR-specific sequences in distinct anatomical districts, have been obtained in rheumatoid arthritis (39) . In fact, V/514 + T cells have been found in higher frequency in synovial fluid of the affected joints than in PBL, and two cDNA clones characterized by particular VB/D/5/J/5 sequences accounted for 46-72% of all V/514 + T cells, making up >4% of all T cells in the affected joints (39) . In our analysis, between 18.4 and 19% of all V/52 + sequences were associated with the tumor-spedfic TCR sequence, thus representing a proportion of similar magnitude (between 1.93 or 2.15%) of all TCR/3 chains present in the tumor infiltrate.
The finding that between 2,000 and 8,000 TCR/5 sequences had to be screened to detect evidence of selective overexpression of a melanoma-specific/5 chain may help to explain the lack of oligodonality detected in other studies based on random sequencing of a smaller set of TCR transcripts obtained from TIL and control PHA blasts (10) . In fact, our results indicate that in order to find evidence of selective expression of some TCR in the lymphoid infiltrate associated with a human tumor, information is needed on the sequence of a TCR shown to be linked to the recognition of the tumor. This information allowed us to upgrade to at least a factor 10, in comparison with previous reports (10), the magnitude of the pool of TCR-specific transcripts that could be analyzed.
The concept that specific TCR might be selectively expressed at the tumor site has been proposed by a previous study (9) showing that ocular melanomas from different patients are characterized by a predominant expression of Vol7, a V region gene segment different from the ones found expressed in the T cell clones of patient 9742. However, since the antigenic specificity of T cells expressing the Voe7 region was not assessed, it remains to be established whether T cells infiltrating ocular melanoma have similar function and antigenic specificity in comparison with CTL clones described in our study. A possibility to be investigated is that normal and neoplastic melanocytes associated with different tissues do not express the same set of genes. Therefore, melanomas from different tissues might express distinct antigenic profiles recognized by distinct sets of TCR. This hypothesis, if proven, may reconcile our results with those of Nitta et al. (9) . However, the issue of which TCR are directed against melanomaassociated antigens is likely to be influenced not only by the antigenic profile of each tumor, but also by the MHC genotype of each patient. Only the comparison of specific antitumor T cells from different patients will clarify the relative contribution of antigens and HLA alleles to the shaping of the antitumor TCR repertoire.
Although the number of TCR sequences described here is too low to draw conclusions on the whole antimelanoma T cell response in patient 9742, the knowledge of TCR ot and /3 chain sequences of human HLA-A2 restricted, melanoma-specific CTL that recognize shared melanoma Ags of broad or more selected distribution provides the molecular basis for studies aimed at defining whether other HLA-A2 + melanoma patients show the same correlation between the fine specificity of antitumor T cell clones and the TCR gene elements they express. If so, the findings described in this study may have an impact on the development of improved therapeutic strategies for the adoptive immunotherapy of melanoma.
Finally, the association between the selective accumulation of a T cell clone at the tumor site and the peculiar antigenic specificity of this effector (namely recognition of Ags expressed not only on the neoplastic cells but also on normal melanocytes) raises the intriguing possibility that at least part of the host reaction to the tumor may be dependent on the recognition of tissue-related self-Ags. Clearly, as discussed in a recent report (15), we do not know whether the Ags recognized by our CTL clones on cultured melanocytes are expressed in vivo by this cell type. However, a possibility to be investigated is that the selective accumulation at the tumor site of a CTL done expressing the V/52.1/D/51/J31.1/C/5 "l'~g reflects a process that has altered at some step the peripheral tolerance to tissue-related self-Ags (40) .
The understanding of the mechanism that underlies both the accumulation/expansion at the tumor site of a melanocytelineage-specific T cell clone and the concomitant failure of an effective block of tumor growth at the same site, represent the next key issue to be addressed for clarifying the reasons of a seemingly insufficient immune response to the metastatic lesion.
